New combo therapy targets rare salivary gland cancer
NCT ID NCT03942653
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 1 time
Summary
This study tests a combination of hormone therapy (goserelin) and an immunotherapy drug (pembrolizumab) in 20 people with advanced salivary gland cancer that cannot be removed by surgery or radiation. The goal is to see if the treatment shrinks tumors or slows the disease. Participants must have a specific type of cancer that tests positive for androgen receptors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SALIVARY GLAND CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Northwestern University Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
Univeristy of Maryland
Baltimore, Maryland, 21201, United States
-
University of Illinois Cancer Center
Chicago, Illinois, 60612, United States
-
University of Iowa Hospitals and Clinics
Iowa City, Iowa, 52242, United States
-
University of Michigan Health System
Ann Arbor, Michigan, 48109, United States
-
University of Minnesota: Masonic Cancer Center
Minneapolis, Minnesota, 55455, United States
-
University of Wisconsin
Madison, Wisconsin, 53705, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new drug combo shrink Hard-to-Treat salivary gland tumors?
- New PET tracer could spot cancers that standard scans overlook
- Drug duo takes on rare head and neck tumors
- New pill-chemo combo takes on hard-to-treat cancers
- Common pain gel could shield cancer patients from radiation burns
- Scientists hunt for immune clues in rare salivary gland cancers